Esperion Therapeutics Inc. (ESPR)

전일 마감가:

$2.09

열려 있는:

$2.13

하루 거래량:

9.42M

시가총액:

$414.92M

수익:

$116.33M

순이익/손실:

$-209.25M

주가수익비율:

-0.7766

EPS:

-2.82

순현금흐름:

$-135.49M

1주 성능:

+5.29%

1개월 성능:

-13.10%

6개월 성능:

+141.94%

1년 성능:

+50.00%

1일 변동 폭

$2.07

$2.215

52주 변동 폭

$0.70

$3.40

Esperion Therapeutics Inc. Stock (ESPR) Company Profile

명칭

Esperion Therapeutics Inc.

부문

Healthcare (1212)

산업

Drug Manufacturers - Specialty & Generic (3)

전화

734-887-3903

주소

3891 Ranchero Drive, Suite 150, Ann Arbor, MI

직원

57

트위터

@esperioninc

다음 수익 날짜

2024-05-23

최신 SEC 제출 서류

ESPR's Discussions on Twitter

Esperion Therapeutics Inc. Stock (ESPR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-16	다운그레이드	BofA Securities	Neutral → Underperform
2023-03-16	다운그레이드	Northland Capital	Market Perform → Under Perform
2023-03-07	업그레이드	Credit Suisse	Underperform → Neutral
2023-02-27	재개	BofA Securities	Neutral
2023-02-24	업그레이드	Jefferies	Hold → Buy
2023-02-03	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	다운그레이드	Credit Suisse	Neutral → Underperform
2022-05-05	업그레이드	JP Morgan	Underweight → Neutral
2022-03-10	개시	H.C. Wainwright	Buy
2021-10-19	다운그레이드	Credit Suisse	Outperform → Neutral
2021-10-14	다운그레이드	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	다운그레이드	Stifel	Buy → Hold
2021-04-26	재개	Credit Suisse	Outperform
2021-03-11	개시	Morgan Stanley	Equal-Weight
2021-02-12	다운그레이드	Jefferies	Buy → Hold
2021-02-09	다운그레이드	Goldman	Neutral → Sell
2021-01-15	다운그레이드	BofA Securities	Buy → Neutral
2020-11-10	업그레이드	Credit Suisse	Neutral → Outperform
2020-09-29	재개	JP Morgan	Underweight
2020-08-11	다운그레이드	Credit Suisse	Outperform → Neutral
2020-04-01	재개	BofA/Merrill	Buy
2020-03-17	업그레이드	Citigroup	Neutral → Buy
2020-02-24	다운그레이드	Northland Capital	Outperform → Market Perform
2020-02-14	다운그레이드	Citigroup	Buy → Neutral
2019-09-16	업그레이드	Goldman	Sell → Neutral
2019-05-29	다운그레이드	Goldman	Neutral → Sell
2019-05-06	업그레이드	BofA/Merrill	Underperform → Neutral
2019-04-26	업그레이드	Goldman	Sell → Neutral
2019-03-13	업그레이드	JP Morgan	Underweight → Neutral
2019-01-07	재확인	Needham	Strong Buy
2018-12-13	개시	Goldman	Sell
2018-10-29	업그레이드	Northland Capital	Market Perform → Outperform
2018-10-16	개시	BTIG Research	Buy
2018-08-17	업그레이드	Citigroup	Neutral → Buy
2018-07-11	다운그레이드	Northland Capital	Outperform → Market Perform
2018-05-03	다운그레이드	JP Morgan	Neutral → Underweight
2018-05-02	다운그레이드	BofA/Merrill	Buy → Underperform

모두보기

Esperion Therapeutics Inc. 주식(ESPR)의 최신 뉴스

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Zacks Investment Research

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Zacks Investment Research

Esperion Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Esperion to Participate in Upcoming May Investor Conferences

GlobeNewswire Inc.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks Investment Research

Esperion Therapeutics Inc. (ESPR) 재무 분석

Esperion Therapeutics Inc. (ESPR) 매출 2024

Esperion Therapeutics Inc. (ESPR) 순이익 2024

Esperion Therapeutics Inc. (ESPR) 현금흐름 2024

Esperion Therapeutics Inc. (ESPR) 주당 순이익 2024